Risperidone Tablet, Orally Disintegrating
NDC Package 59746-010-22

11-digit billing NDC: 59746001022

Package Information

Risperidone tablets is tablet AccessingRisperidone Orally Disintegrating Tablets 0.5 mg and 1 mg  Risperidone Orally Disintegrating Tablets 0.5 mg and 1 mg are supplied both in blister packs of 4 and blister packs of 10 tablets. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Jubilant Cadista Pharmacuticals Inc., this product is identified by NDC 59746-010 and is authorized under FDA application ANDA090839.

Identification & Billing

NDC Package Code
59746-010-22
Package Description
7 BLISTER PACK in 1 CARTON / 4 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
Product Code
11-Digit Billing Format
59746001022
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Risperidone
Non-Proprietary Name
Risperidone
Substance Name
Risperidone
Dosage Form
Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Tablet AccessingRisperidone Orally Disintegrating Tablets 0.5 mg and 1 mg  Risperidone Orally Disintegrating Tablets 0.5 mg and 1 mg are supplied both in blister packs of 4 and blister packs of 10 tablets.   Do not open the blister until ready to administer. For single tablet removal, separate one of the four or ten blister units by tearing apart at the perforations. DO NOT push the tablet through the foil because this could damage the tablet. Peel back at pull tab to expose the tablet. Risperidone Orally Disintegrating Tablets 2 mg, 3 mg and 4 mg  Risperidone Orally Disintegrating Tablets 2 mg, 3 mg and 4 mg are supplied in blister pack of 4 tablets each.   Do not open the blister until ready to administer. For single tablet removal, separate one of the four blister units by tearing apart at the perforations. DO NOT push the tablet through the foil, because this could damage the tablet. Peel back at pull tab to expose the tablet. Tablet AdministrationUsing dry hands, remove the tablet from the blister unit and immediately place the entire Risperidone Orally Disintegrating Tablet on the tongue. The Risperidone Orally Disintegrating Tablet should be consumed immediately, as the tablet cannot be stored once removed from the blister unit. Risperidone Orally Disintegrating Tablets disintegrate in the mouth within seconds and can be swallowed subsequently with or without liquid. Patients should not attempt to split or to chew the tablet.

Regulatory & Marketing

Labeler Name
Jubilant Cadista Pharmacuticals Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA090839
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-04-2011
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (59746-010). Click a package code to view its specific billing and regulatory data.

3 BLISTER PACK in 1 CARTON / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59746-010-22 identifies a specific commercial package of 7 blister pack in 1 carton / 4 tablet, orally disintegrating in 1 blister pack of Risperidone, a human prescription drug labeled by Jubilant Cadista Pharmacuticals Inc.. This tablet, orally disintegrating is formulated for oral use and contains risperidone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jubilant Cadista Pharmacuticals Inc. on November 04, 2011. The current certification is valid through December 31, 2026.

How is this Jubilant Cadista Pharmacuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59746001022. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59746-010-22
11-Digit CMS (5-4-2)
59746-0010-22

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.